TABLE 1.

Percentage (%) alterations (*amplification, **mutations, ***deep deletion, ****multiple alterations) in GEFs of multiple cancers from the TCGA PanCancer Atlas (Cerami et al., 2012; Gao et al., 2013).

Type of Cancer	Tiam-1	Trio	P-Rex1	P-Rex2	Vav1	Vav2	Vav3	Dock1	Ect2
Esophageal Squamous Cell Carcinoma	**2.11%	*16.8%	**3.16%	**1.05% *3.16%	**1.05% ***1.05%	*2.11%	0%	**1.05% *1.05%	*28.42%
Ovarian Epithelial Tumor	***1.2%	**1.54% *7.02%	**1.71% *2.91%	**1.2% *5.99%	*1.03%	0%	0%	*2.74%	*23.12%
Non-small cell lung cancer	**7.69%	*11.02% **5.13%	**6.17% *1.04%	**6.74% *1.99%	**2.37%	**1.8%	**3.8%	**1.99%	*19.37%
Head and Neck Squamous Cell Carcinoma	**2.29%	**3.44% *3.63%	**2.49%	**3.25% *2.68%	**1.34%	0%	0%	**2.68%	*16.73%
Undifferentiated Stomach Adenocarcinoma	**15.38%	**7.69%	*7.69% **7.69%	***7.69%	0%	0%	0%	**7.69%	0%
Endometrial Carcinoma	**10.75%	**13.31%	**6.83% *2.05%	**7.51% *2.56%	**5.8%	**5.63%	**5.63%	**11.77%	**4.27% *7.34%
Cervical adenocarcinoma	**4.35%	**2.17%	*2.17%	**2.17%	***2.17%	**4.35%	**4.35%	**2.17%	*8.7% ****2.17
Esophagogastric Adenocarcinoma	**6.61%	**8.17% *4.28%	**4.09% *3.11%	**12.26%	**2.72%	**2.14%	**2.92%	**3.89% *1.36%	**1.17% *5.84%
Pancreatic Adenocarcinoma	**1.63%	0%	**2.72%	**1.09% * 3.8%	**1.63%	0%	0%	**1.63%	**2.17% * 2.72%
Invasive Breast Cancer	0%	**1.38% *2.4%	**1.11%	**2.03% *5.17%	0%	0%	0%	**1.11%	*2.58%
Colorectal Adenocarcinoma	**6.06%	**5.89%	**4.88% *6.57%	**6.73% *2.19%	**2.53%	**1.85%	**3.03%	**4.21%	**2.53%
Prostate Adenocarcinoma	0%	**1.21%	*1.01%	*6.48%	0%	*1.21%	**1.01%	0%	*2.43%
Glioblastoma	0%	**1.52%	**1.52%	0%	**1.18%	0%	0%	**1.18%	*1.01%
Melanoma	**9.01%	**10.14% ***1.13	**5.41% ***1.13%	**22.52% ***1.35%	**8.11%	**3.60%	*1.35% **5.41%	**7.43%	**4.05%